Eli Lilly and Co (LLY.N)
19 Oct 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2017||Chairman of the Board, President, Chief Executive Officer|
|48||2018||Chief Financial Officer, Senior Vice President|
|64||2010||Executive Vice President - Science and Technology, President - Lilly Research Laboratories|
|53||2018||Senior Vice President - Information Technology, and Chief Information Officer|
|50||2013||Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer|
- Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
- UPDATE 1-Express Scripts covers Amgen, Lilly migraine drugs, excludes Teva
- UPDATE 2-Minnesota accuses insulin makers of deceptive drug pricing
- Minnesota accuses insulin makers of deceptive drug pricing
- US STOCKS-Wall Street stumbles as bond yield climb continues